Incyte Corporation (INCY)
Healthcare · Biotechnology · Data as of 2026-10-22
Bottom line
INCY is trading near its usual valuation, in the middle of its recent price range, and recent volume suggests money flowing out. The picture is mixed, so it may be worth watching rather than acting on. Past patterns are not a guarantee of future results.
Valuation — Priced about in line with its growth (Yellow)
For a fast-growing company like INCY (revenue is growing about 21% a year), we weigh next year's expected P/E of 36× against the 152% earnings growth analysts expect, counting at most 30% a year because growth that fast rarely lasts (a forward PEG of 1.21, 14 estimates). That is a fairly typical trade-off. Its current multiple sits around the 7th percentile of its own last five years — toward the low end of its own range.
Price zones — In the middle of its recent range (Yellow)
At $116.93, the stock sits between its recent support and resistance levels. Over the past year INCY has traded between $84.02 and $132.60; its historical support zone sits near $107.76 and resistance near $121.36. It is above one of its moving averages and below the other — a mixed trend picture.
52-week range $84.02–$132.60 · 50-day average $121.36 · 200-day average $107.76
Money flow — Money is flowing out (Red)
Recent trading in INCY shows more volume on falling days than rising days, a pattern often described as distribution. Volume on up days has been about 0.5× volume on down days over the last 30 sessions.
Dividends & company facts
INCY doesn't pay a dividend, and it issued more shares than it bought back in fiscal 2025. Its share count rose 4.8% over the past year.
- Shares, past year
- +4.8%
- Revenue, 12 months
- $5.8B
- Profit, 12 months
- $1.6B
- Employees
- 2,844
- CEO
- William J. Meury
- Headquarters
- Wilmington, DE
- Listed since
- 1993 · NASDAQ
About the company
Incyte Corporation is a biopharmaceutical firm engaged in the research, development, and global marketing of its own innovative therapies. Its current product offerings include JAKAFI, prescribed for myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia. Beyond its marketed drugs, Incyte's pipeline features several promising candidates.
Related stocks
一句话结论
INCY 估值接近其惯常水平，处于近期价格区间的中部，近期成交量显示资金正在流出。整体情况好坏参半，也许更适合先观察，而不是急于行动。过去的形态并不能保证未来的结果。
估值 — 价格与其增长大致相称
对 INCY 这样的高增长公司（营收年增长约 21%），我们把它明年的预期市盈率 36× 与分析师预计的 152% 盈利增速放在一起看，但增速最多按每年 30% 计算，因为这么快的增长很少能持续（前瞻 PEG 为 1.21，来自 14 份预测）。这是相当常见的一种取舍。它当前的估值倍数大约位于自身过去五年分布的第 7 百分位——处于自身区间的偏低位置。
价格区间 — 处于近期区间的中部
目前价格为 $116.93，位于其近期的支撑位与阻力位之间。过去一年 INCY 的价格在 $84.02 到 $132.60 之间波动；其历史支撑区在 $107.76 附近，阻力区在 $121.36 附近。它位于其中一条均线上方、另一条下方——趋势信号并不一致。
资金流向 — 资金正在流出
INCY 近期下跌日的成交量高于上涨日，这种形态常被称为派发。过去 30 个交易日，上涨日的成交量约为下跌日的 0.5×。
股息与公司概况
INCY 不派发股息，并且在 2025 财年发行的股票多于回购的股票。其股数过去一年增加了 4.8%。
UnderTheLight 用直白的语言解释股票——估值、价格区间与资金流向。它只描述数据，不构成任何投资建议。
UnderTheLight explains stocks in plain English — valuation, price zones and money flow as traffic lights, recomputed nightly. It describes data; it is not investment advice and never recommends a trade.